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Abstract
Summary To reach a Spanish expert consensus on a treat-to-
target strategy in osteoporosis, a Delphi Consensus Study has
been developed. Most of the experts (59.8%) were rheumatol-
ogist with a mean clinical experience of 21.3 years (SD 8.5).
Consensus was achieved for 70% of the items. Therapeutic
objectives, patient follow-up scheme, treatment failure
criteria, and appropriate treatment choice for use in T2T strat-
egy in Spain have been defined.
Introduction The paper aims to achieve a Spanish expert con-
sensus on a treat-to-target (T2T) strategy in osteoporosis.
Methods A scientific committee led the project and was in-
volved in expert panel identification and Delphi questionnaire
development. Two Delphi rounds were completed. The first-
round questionnaire included 24 items and assessed, using a
seven-point Likert scale, the experts’ wish (W) and prognosis
(P) in 5 years for each topic (applicability, therapeutic objec-
tives, patient follow-up, and possible treatment to be pre-
scribed). Items for which there was no consensus in the first
round were included in the second round. Consensus was de-
fined as ≥75% agreement (somewhat/mostly/entirely agree) or
disagreement (somewhat/mostly/entirely disagree) responses.
Results Of the experts, 112 and 106 completed the first and
second rounds, respectively. 59.8%were rheumatologists with
a mean clinical experience of 21.3 years (SD 8.5). Consensus
was achieved for 70% of the items, and was established re-
garding the utility of a T2T strategy to define therapeutic ob-
jectives, optimal follow-up, and therapeutic algorithm.
Participants agreed on the utility of the bone mineral density
(BMD) value (T-score >−2.5 SD for spine and >−2.5/−2.0 SD
for femoral neck), lack of fractures, and fracture risk (FRAX)
as therapeutic objectives. For measuring BMD changes, con-
sensus was achieved on the suitability of hip and femoral neck
locations. Experts agreed to consider treatment failure as when
a significant BMD gain could not be achieved, or when a new
fracture occurs within 2–3 years. There was consensus that all
proposed therapies should achieve a therapeutic target through
T2T strategy (treatments with the highest consensus scores
were denosumab and teriparatide).
Conclusion The therapeutic objectives, patient follow-up
scheme, treatment failure criteria, and appropriate treatment
choice for use in T2T strategy in Spain have been established
by a panel of experts. Some aspects nevertheless still require
further analysis.
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Introduction
Osteoporosis is a highly prevalent chronic disease characterized
by decreased bone strength, the main clinical consequence of
which is fragility fracture [1]. Drug treatment for osteoporosis is
based on the presence of fragility fractures, measurement of
bone mineral density (BMD), or fracture-risk assessment, usu-
ally determined by the Fracture Risk Assessment Tool (FRAX)
score. Patients are monitored in clinical practice by measure-
ments of BMD and, occasionally, bone-turnover markers
(BTMs). A therapeutic intervention is deemed successful if no
new fractures occur, BMD increases or remains stable, and
BTMs change appropriately. There is still controversy, howev-
er, as to whether treatment should be maintained indefinitely
under these circumstances [2]. In contrast, many other chronic
diseases (e.g., diabetes, hypertension, dyslipidemia, and rheu-
matoid arthritis) have well-established treatment goals with
which to facilitate the medical management of the disease, thus
enabling a Btreat-to-target^ (T2T) strategy [3].
A biomarker is a measure that is indicative of a physiolog-
ical process, a disease process, or a pharmacological response
to an intervention. In order to establish a T2T strategy, it is
first of all necessary to identify an appropriate biomarker
for the disease follow-up process and to establish its
threshold. Recently, some authors and scientific societies
(such as the International Osteoporosis Foundation (IOF)
and the American Society for Bone and Mineral Research
(ASBMR)) have proposed that a T2T strategy could be
helpful for osteoporosis treatment [4–6]. The general aim
of T2T is to simplify management, and ultimately to reduce
organ damage and improve clinical outcomes [4]. In par-
ticular, in the field of osteoporosis, T2T strategy is
intended to individualize the initial choice of treatment
based on the probability of achieving the goal for a patient.
Moreover, decisions about stopping, discontinuing, chang-
ing, or continuing treatment may be also based on an
established therapeutic target. Analyses of data available
in the main placebo-controlled randomized trials with frac-
ture as a primary endpoint could be the most suitable ap-
proach for identifying the best targets. However, the per-
formance of biomarkers available for a T2T strategy has
been questioned by some authors on the grounds that it is
not easy to implement [7]. There are no established con-
sensus goals for BMD, BTM, or fracture risk in the treat-
ment of osteoporosis. Recently, societies such as ASMBR
and the United States National Osteoporosis Foundation
(NOF) have encouraged the idea of performing further
comparative studies and analyses to define treatment goals
in order to apply T2T strategy [8]. Fortunately, the signif-
icant impact of new anti-osteoporotic drugs on enhancing
BMD and its relationship with lowering fracture risk could
change this scenario [9].
In the present situation, the development of a comprehen-
sive process for yielding consensus among experts in osteo-
porosis is the best approach for establishing a T2Tstrategy and
for assessing its possible future implementation in clinical
practice. Delphi technique was therefore implemented to ana-
lyze the degree of consensus on T2T strategy in osteoporosis
among Spanish specialists.
Methods
Two Delphi rounds were performed to establish consensus
regarding the T2T strategy in osteoporosis. The Delphi tech-
nique is a structured method widely used to gather important
information on a specific topic. It is based on a series of ques-
tionnaires or Brounds^ addressed to experts. The key features
of this method are the anonymity of participants and con-
trolled feedback [10–12].
Scientific committee
The project was led by a scientific committee that was com-
posed of six experts in bone metabolism (three endocrinolo-
gists, two rheumatologists, and one medical internist), who
were selected by the main medical societies in bone metabo-
lism (Spanish Society of Bone and Mineral Metabolism
Research [SEIOMM] and Spanish Rheumatology Society
[SER]). The scientific committee took part in the identifica-
tion of the study participants (expert panel) and assisted in
drawing up, reviewing, and approving the specific question-
naire developed for use during the Delphi rounds. Its members
likewise validated and analyzed the results of the study.
Expert panel
The scientific committee selected 165 participants. The
criteria for their selection included professional knowledge
and experience in the field of osteoporosis, and practice in
the Spanish Health System, as well as active membership of
any of the scientific societies that collaborated in the study
(henceforth they are referred to as experts).
There is little consensus in the literature concerning the
optimal sample size of a Delphi study [13–15]. Some studies
showed that experts who have similar training and general
understanding in the field of interest allow for effective and
reliable utilization of a small sample [16].
490 Osteoporos Int (2018) 29:489–499
Questionnaire
The development of the first-round questionnaire involved a
systematic review of the literature on osteoporosis, including
articles referring to T2T. Once the main aspects of this strategy
were identified, a discussion group defined the aspects to be
included in the questionnaire with the scientific committee.
The first round of the electronic questionnaire included 24
items (176 aspects) involved in the T2T strategy on osteopo-
rosis. These were distributed in four blocks: (1) applicability,
(2) therapeutic objectives to be established, (3) patient follow-
up, and (4) possible treatment to be prescribed. All items were
drafted as assertions to be answered from two perspectives:
wish (desire for it to happen) and prognosis (belief that it will
happen) in a 5-year period. A seven-point Likert scale was
used for each answer (entirely disagree/mostly disagree/some-
what disagree/neither agree nor disagree/somewhat agree/
mostly agree/entirely agree). An open space in which to ex-
press any opinions was also provided.
It is important to consider that questions included in blocks
1, 2, and 3 were raised on a general basis and with no reference
to a specific drug.
Definition of consensus
Definition of consensus was established before data analyses. It
was determined that consensus would be achieved if at least
75% of participants reached agreement (entirely agree, mostly
agree, or somewhat agree) or disagreement (entirely disagree,
mostly disagree, or somewhat disagree) [11, 17, 18]. The con-
sensus regarding agreement or disagreement was considered to
be strong when over 75% of the participants responded entirely
agree/mostly agree or entirely disagree/mostly disagree [18].
Chronogram of Delphi rounds
The first round took place between 11 and 27 May 2015. The
aspects about which respondents did not reach consensus in
this first round (18 items that evaluated 78 aspects) were in-
cluded in the second round. Accordingly, controlled feedback
relating to ratings gathered from the group during the first
round was provided for each item. Participants had the oppor-
tunity to alter their initial rating, based on the group responses.
The second round took place between 8 and 21 June 2015.
Data analyses
A database was created using SPSS Statistics version 20 by
IBM (Armonk, NY, USA). Percentages for each response
were calculated for both studied perspectives (wish and prog-
nosis). A proportion within a range method was used to define
consensus [11].
Ethical aspects
This study was performed in accordance with the Helsinki
Declaration. All the personal data included in the study were
dissociated from the results and kept anonymous, in compli-
ance with Spanish law on data protection [19].
Results
Participants’ characteristics
One-hundred and sixty-five experts from all over Spain were
invited to participate by e-mail. Of these, 112 answered the
first-round questionnaire (67.88% of the experts contacted)
and 106 the second-round questionnaire (including 94.6% of
the experts who answered the first round). Of these, 65.2%were
male, had a mean experience of 21.3 years (SD 8.5), and visited
a median of 70 patients per month (IQR between 40 and 100).
Most of the participants were rheumatologists (59.8%), followed
by internists (14.3%) and endocrinologists (10.7%).
Achieved consensus
Consensus was reached on 70% of issues, 44% of them being
reached in the first Delphi round.
a) Applicability of T2T strategy in osteoporosis
Most of the participants (wish 96.4% and prognosis 82.1%)
agreed that, on the basis of T2T strategy, it should be possible
to establish a well-defined therapeutic objective, to propose an
optimal follow-up scheme, and to provide insight on the ther-
apeutic strategy.
b) Therapeutic objectives
Assessment of the therapeutic objectives to be established in
a T2Tstrategy for osteoporosis was based on 13 items (Table 1).
There was consensus that the absence of new fractures, an in-
crease in BMD, a significant change in BTMs, and fracture risk
reduction measured by FRAX could be used as therapeutic ob-
jectives. Experts also agreed that all preceding parameters, ex-
cept BTM, will be used in the next 5 years (Fig. 1). It is impor-
tant to note that strong consensus was reached only on the use of
absence of new fractures as a therapeutic objective (wish 93.8%;
prognosis 82.1%) (Table 1 and Fig. 1).
As far as BMD is concerned, it was established that this
should be measured using a tangible absolute value, or as a
predetermined difference between two values. Scores higher
than −2.5 SD were the only tangible absolute values for spine
T-score, for which consensus was achieved from both the wish
and prognosis perspectives. As far as femoral neck T-score
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Table 1 Results related to
therapeutic objectives to be
established in T2T strategy in
osteoporosis
Question Wish (%) Prognosis (%)
A I D A I D
For establishing a therapeutic objective, has to be considered
a. patient age 97.3 0.9 1.8 98.2 0.9 0.9
b. baseline T-score 94.6 1.8 3.6 94.6 2.7 2.7
The therapeutic objective is to be achieved
a. rapidly 75.0 2.7 22.3 93.4 3.8 2.8
b. constantly and consistently maintained 96.4 1.8 1.8 93.8 3.6 2.7
The following parameters could be used as therapeutic objectives in the context of the T2T strategy in
osteoporosis
a. BTM 86.8 3.8 9.4 60.6 10.4 29.2
b. BMD 91.1 0.9 8.0 91.1 6.3 2.7
c. fracture risk reduction measured FRAX 75.9 8.0 16.1 84.0 6.6 9.4
d. absence of new fractures 99.1 – 0.9 97.3 0.9 1.8
The BMD (measured with the T-score) has to be used as the
principal parameter for defining an adequate therapeutic ob-
jective in the context of the T2T strategy in osteoporosis
83.0 1.8 15.2 83.9 4.5 11.6
If BMD is used as the principal parameter for defining an adequate therapeutic objective, it has to be measured
using a
a. tangible absolute value 88.7 – 11.3 92.5 0.9 6.6
b. predetermined difference between two values 85.7 7.1 7.1 82.1 12.5 5.4
If BMD is used as the principal parameter for defining an adequate therapeutic objective, the target lumbar spine
T-score to be achieved is
a. >−2.5 SD 75.9 8.0 16.1 92.5 0.9 6.6
b. >−2.0 SD 64.3 13.4 22.3 53.6 24.1 22.3
c. >−1.5 SD 39.9 19.6 41.1 30.4 25.9 43.8
d. >−1.0 SD 24.1 21.4 54.5 18.8 22.3 58.9
e. an increment of 2 SD with reference to the baseline BMD 81.1 3.8 15.1 83.0 3.8 13.2
f. an increment in the basal BMD (any change) 86.8 2.8 10.4 86.8 4.7 8.5
If BMD is used as the principal parameter for defining an adequate therapeutic objective, the target femoral
(femoral neck of total hip) T-score to be achieved is
a. >−2.5 SD 79.5 3.6 17.0 79.5 7.1 13.4
b. >−2.0 SD 77.7 7.1 15.2 93.4 1.9 4.7
c. >−1.5 SD 46.4 14.3 39.3 38.4 22.3 39.3
d. >−1.0 SD 30.4 15.2 54.5 23.2 18.8 58.0
e. an increment of 2 SD with reference to the baseline BMD 84.9 4.7 10.4 84.0 3.8 12.3
f. an increment in the basal BMD (any change) 86.8 10.4 2.8 86.8 3.8 9.4
If fracture risk reduction is used as the principal parameter for defining an adequate therapeutic objective, it has to
be measured using
a. FRAX 85.8 2.8 11.3 87.7 4.7 7.5
b. Q-fracture 59.4 24.5 16.0 31.1 54.7 14.2
c. Garvan 28.3 40.6 31.1 9.4 74.5 16.0
If fracture risk reduction is used as the principal parameter for defining an adequate therapeutic objective, it has to
be measured using a
a. tangible percentage 89.6 2.8 7.5 91.5 2.8 5.7
b. predetermined difference between two values 86.8 4.7 8.5 87.7 5.7 6.6
If fracture risk reductionmeasured by FRAX is used as the principal parameter for defining an adequate therapeutic
objective, the risk of major fractures (hip, vertebral, femur, humerus, and radius) has to be lower than
a. 5% 55.7 1.9 42.5 50.9 2.8 46.2
b. 7.5% 72.6 2.8 24.5 63.2 5.7 31.1
c. 10% 75.5 2.8 21.7 68.9 4.7 26.4
d. 20% 43.4 1.9 54.7 41.5 3.8 54.7
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value was concerned, there was consensus that scores higher
than −2.5 and −2.0 SD should be established as a therapeutic
objective.
c) Patient follow-up
From both perspectives (wish and prognosis), there was
consensus that the three anatomic areas suggested in the
Delphi questionnaire (lumbar spine, femoral neck, and total
hip) were useful for monitoring BMD in patients who have
already been treated (Table 2). It is noteworthy that a strong
consensus was established in both perspectives related to the
usefulness of femoral neck area (wish 99.1%; prognosis
98.2%).
d) Treatment prescribed
Six items of the survey assessed matters related to the treat-
ment prescribed in a hypothetical T2T strategy for osteoporo-
sis (Table 3).
Participants deemed that all drugs, except strontium
ranelate, were suitable for a T2T strategy.
According to expert opinion, the most suitable drug
for this strategy is denosumab (for which there was over
97% agreement), followed by teriparatide (96.4% agree-
ment). There was, on the other hand, considerable dis-
agreement, both regarding wish and prognosis, on
whether strontium ranelate is a suitable drug for a T2T
strategy.
Table 1 (continued)
Question Wish (%) Prognosis (%)
A I D A I D
If the absence of new fractures is used as the principal parameter for defining an adequate therapeutic objective,
the incidence of fractures has to be measured using
a. VFA 83.0 10.7 6.3 92.5 0.9 6.6
b. height 75.9 8.9 15.2 94.3 2.8 2.8
c. conventional X-ray 88.4 5.4 6.3 83.9 8.0 8.0
d. major nonvertebral fragility fracture (humerus, radius, and
femur)
96.4 2.7 0.9 95.5 2.7 1.8
e. any fracture (including pelvic branches and other long bones) 91.1 7.1 1.8 85.7 8.9 5.4
BTM are good therapeutic indicators for
a. determining the therapeutic objective 79.2 5.7 15.1 64.2 5.7 30.2
b. selecting population to be treated 29.2 5.7 65.1 21.7 5.7 72.6
c. establishing a therapeutic strategy 52.8 9.4 37.7 43.4 9.4 47.2
d. performing treatment follow-up 83.9 7.1 8.9 78.6 11.6 9.8
If BTM are used as the principal parameter for defining an adequate therapeutic objective, they have to be
measured using a
a. tangible absolute value 58.5 7.5 34.0 42.5 10.4 47.2
b. predetermined difference between two values 79.5 10.7 9.8 95.3 3.8 0.9
Italic values represent the most answered option
A agreement, I indifference,D disagreement, wish (desire for it to happen), prognosis (belief that it will happen in
a 5-year period)
Consensus ≥75%
%
 E
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er
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 a
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m
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t
* A strong consensus was reached
Fig. 1 Reported expert
agreement among therapeutic
objectives to be established in
T2T strategy
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A drug holiday following the achievement of a ther-
apeutic objective seems a good strategy and achieved
over 80% agreement, for bisphosphonates, strontium
ranelate, and denosumab. However, when using selective es-
trogen-receptor modulator (SERM), there was no agree-
ment on the best option after the objective has been achieved.
e) Treatment failure
From wish and prognosis perspectives, there was consensus
that treatment failure should be considered whenever the BMD
increment is not achieved within 2 or 3 years, a new fracture is
diagnosed over 2 or 3 years, or a significant change in BTM is not
achieved in the following 6months or 1 year (Table 4 and Fig. 2).
Table 3 Results related to
treatments to be prescribed in T2T
strategy on osteoporosis
Question Wish (%) Prognosis (%)
A I D A I D
The T2T strategy in osteoporosis is possible with the following anti-osteoporotic treatment:
a. oral bisphosphonates 88.4 5.4 6.3 88.4 3.6 8.0
b. intravenous bisphosphonates 92.0 6.3 1.8 89.3 6.3 4.5
c. SERM 94.3 1.9 3.8 96.2 – 3.8
d. strontium ranelate 76.4 5.7 17.9 58.5 4.7 36.8
e. denosumab 97.3 1.8 0.9 94.6 3.6 1.8
f. teriparatide 96.4 1.8 1.8 92.0 4.5 3.6
g. denosumab plus teriparatide 80.4 11.6 8.0 78.6 10.7 10.7
h. developing treatments 86.6 11.6 1.8 81.3 13.4 5.4
In patients treated with bisphosphonates, once the therapeutic objective has been reached, the treatment has to be
a. stopped for a period of time (drug holiday) 81.3 2.7 16.1 77.7 6.3 16.1
b. continued indefinitely 12.5 1.8 85.7 10.7 9.8 79.5
c. switched 5.7 1.9 92.5 5.7 1.9 92.5
In patients treated with SERM, once the therapeutic objective has been reached, the treatment has to be
a. stopped for a period of time (drug holiday) 34.0 3.8 62.3 36.8 4.7 8.5
b. continued indefinitely 16.1 7.1 76.8 17.0 8.0 75.0
c. switched 32.1 4.7 63.2 26.4 7.5 66.0
In patients treated with strontium ranelate, once the therapeutic objective has been reached, the treatment has to be
a. stopped for a period of time (drug holiday) 84.0 7.5 8.5 83.0 8.5 8.5
b. continued indefinitely 8.9 8.0 83.0 8.9 10.7 80.4
c. switched 67.9 6.6 25.5 68.9 6.6 24.5
In patients treated with teriparatide, once the therapeutic objective has been reached, the treatment has to be
a. stopped for a period of time (drug holiday) 75.5 1.9 22.6 76.4 1.9 21.7
b. continued indefinitely 3.6 2.7 93.8 2.7 4.5 92.9
c. switched 80.4 3.6 16.1 77.7 5.4 17.0
In patients treated with denosumab, once the therapeutic objective has been reached, the treatment has to be
a. stopped for a period of time (drug holiday) 81.1 – 18.9 84.9 – 15.1
b. continued indefinitely 8.5 – 91.5 6.6 0.9 92.5
c. switched 15.1 2.8 82.1 12.3 3.8 84.0
Italic values represent the most answered option
A agreement, I indifference,D disagreement, wish (desire for it to happen), prognosis (belief that it will happen in
a 5-year period)
Table 2 Results related to follow-up of people with osteoporosis using
a T2T strategy
Question Wish (%) Prognosis (%)
A I D A I D
For monitoring the BMD in patients already treated, the following
anatomic can be useful:
a. lumbar spine 96.4 0.9 2.7 96.4 0.9 2.7
b. femoral neck 99.1 – 0.9 98.2 1.8 –
c. total hip 92.0 5.4 2.7 92.0 6.3 1.8
Italic values represent the most answered option
A agreement, I indifference, D disagreement, wish (desire for it to
happen), prognosis (belief that it will happen in a 5-year period)
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Discussion
To our knowledge, this is the first expert consensus regarding
the applicability of a T2T strategy for osteoporosis in clinical
practice. The results of Spanish consensus on T2Tstrategy for
osteoporosis using Delphi methodology are presented. The
study results reflect data not only from pivotal studies but also
from post-authorization studies and, above all, the clinical
experience of experts.
A treating strategy with which to achieve a well-predefined
goal is a feature of different areas of medicine. T2T strategy
has thus been widely applied in the fields of diabetes [3],
Table 4 Results related to
therapeutic-failure definition Question Wish (%) Prognosis (%)
A I D A I D
Therapeutic failure is to be considered when the BMD increment is not achieved in
a. 6 months 8.9 2.7 88.4 5.4 8.0 86.6
b. 1 year 35.7 4.5 59.8 33.9 8.9 57.1
c. 2 years 81.3 6.3 12.5 82.1 4.5 13.4
d. 3 years 77.7 8.0 14.3 75.9 9.8 14.3
e. 5 years 67.0 9.8 23.2 65.2 11.6 23.2
f. >5 years 51.8 13.4 34.8 48.2 19.6 32.1
Therapeutic failure is to be considered when a new fracture is diagnosed in the following:
a. 6 months 38.4 6.3 55.4 33.9 10.7 55.4
b. 1 year 77.7 8.0 14.3 77.7 8.0 14.3
c. 2 years 92.0 2.7 5.4 92.0 4.5 3.6
d. 3 years 90.2 4.5 5.4 88.4 7.1 4.5
e. 5 years 79.5 8.9 11.6 79.5 9.8 10.7
f. >5 years 69.6 11.6 18.8 68.8 13.4 17.9
Therapeutic failure is to be considered when a significant change in bone-remodeling markers is not achieved in
the following:
a. 1 month 1.9 3.8 94.3 0.9 3.8 95.3
b. 3 months 73.6 4.7 21.7 59.4 6.6 34.0
c. 6 months 75.0 16.1 8.9 93.4 2.8 3.8
d. 1 year 90.6 4.7 4.7 89.6 5.7 4.7
e. 2 years 68.9 4.7 26.4 67.9 5.7 26.4
f. >2 years 65.1 2.8 32.1 61.3 4.7 34.0
Italic values represent the most answered option
A agreement, I indifference,D disagreement, wish (desire for it to happen), prognosis (belief that it will happen in
a 5-year period)
New fracture No BMD increment No significant 
change in BTM
Consensus ≥75%
%
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er
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t
Fig. 2 Reported expert
agreement related to therapeutic
failure definition
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hypertension [20], hypercholesterolemia [21], and rheumatoid
arthritis [22, 23]. In osteoporosis, it has also recently become a
matter of interest. Its role in this context remains controversial.
T2T is an attractive approach for application in order to avoid
the perpetuation of treatment and possible adverse effects,
provided that the desired goal is achieved. The problem begins
when a measurable and sensitive tool is required to assess the
achievement of the final objective. Capturing the change in
fracture risk associated with treatment is not easy. Strong ev-
idence is needed to confirm that selecting and switching treat-
ment reduces fracture risk more effectively than the current
standard of care [8].
Since we have treatments to modify the bone-remodeling
process, the ultimate objective has always been the reduction
of fragility fractures [1]. Given that two new issues have ap-
peared in the field of osteoporosis, the need to establish a
therapeutic goal has become evident [4]. Some treatments,
such as anti-sclerostin or denosumab, have demonstrated a
high increase in BMD after short periods of treatment, with
most patients reaching normal range T-score values when
evaluated by dual-energy X-ray absorptiometry (DXA) mea-
surements [24, 25].
Until now, however, the measurable goal has never been
attempted, and when it was attained, debate centered upon
whether the treatment should be stopped, changed, or at least
reconsidered, given that fragility fractures could reappear if
some treatments were discontinued. We have therefore ana-
lyzed the current thinking of Spanish experts in bone metab-
olism, on the basis of two perspectives: the wish or desire for
occurrence and the prognosis or belief that, upon consider-
ation of the field and resources, this will be put into practice
within a 5-year period.
Wide consensus arose when experts were asked about the
feasibility of establishing a well-defined objective in osteopo-
rosis. Almost all participants agreed on the possibility of ap-
plying T2T strategy in clinical practice in osteoporosis.
Consensus usually arises in Delphi methodology when agree-
ment or disagreement ranges from 50 to 80% [26]. In this case,
agreement exceeded 95%, which could indicate that Spanish
physicians have a strong desire to have a T2T for osteoporosis
management.
There was consensus that the parameters used as therapeu-
tic objectives in the context of the T2Tstrategy in osteoporosis
should be the absence of new fractures, a specific BMD value,
and, at a lower level, BTM and fracture-risk reduction mea-
sured by FRAX. Many physicians do not have access to BTM
and the use of FRAX is not general practice. Consequently, its
implementation as a target is less feasible.
FRAX does not seem to be a good tool for measuring the
reduction in fracture risk achieved with treatments. However,
75.9% of the experts would wish a therapeutic objective of a
10-year risk of fracture measured with a tool such as FRAX.
Furthermore, 84% of them predicted that FRAX, probably
with certain adjustments, will become a useful tool for a
T2T strategy in osteoporosis. With regard to this hypothetical
situation, Leslie et al. [27] demonstrated in the Manitoba co-
hort population that the increase in FRAX score over time
after therapy was lessened, albeit not prevented. Actually, this
hypothetical situation is almost impossible in the real life. In
fact, Leslie et al. [27] demonstrated in the follow-up of
Manitoba cohort that a small percentage of patients, even with
a medication possession rate >0.8, achieved reduction in ma-
jor fracture probability of 4% or higher. Therefore, we believe
that the result of the question regarding FRAX reduction, even
though it could be used as the principal parameter for defining
an adequate therapeutic objective, is more a wish than a real-
ity. It might reflect the desire of having in the future a tool
more linked to a reduction of the risk in patients on treatment.
Consensus was established regarding the utility of BMD as
a principal parameter for defining an adequate therapeutic
objective. In line with that, it was established that BMD
should be measured using a tangible absolute value, or as a
predetermined difference between two values. Scores higher
than −2.5 SD for spine T-score were the only tangible absolute
values, for which there was consensus for both perspectives.
As far as femoral neck T-score value is concerned, there was
consensus that scores of over −2.5 or −2.0 SD, which are
almost the same threshold values for osteopenia and osteopo-
rosis in the WHO definition [28], should be established as a
therapeutic objective. The FLEX study [29] showed that
the T score −2.5 was the optimal point to be achieved in
order to prevent new nonvertebral fractures. Moreover, the
results suggested that there was no advantage in continuing
with alendronate. In our study, a T score of −2.0 was in-
cluded on the basis of the FREEDOM study [9]. The re-
sults of the FREEDOM study suggested that the reduction
of nonvertebral fracture risk associated with denosumab
was influenced by the hip BMD achieved with initial
therapy [9].
There was discussion regarding the T-score threshold and
the site of BMD measurement. It seems that spine BMD is
influenced by several artifacts such as osteophytes, vascular
calcifications, and sclerosis, and such factors could bias the
real results [30]. Femoral-neck BMD, meanwhile, reflects
more cortical bone, whereas total hip measures cortical and
trabecular bone [31]. The first step to establish a measurable
mark for T2T strategy would therefore be to select the proper
location for measuring BMD. Despite all these technical con-
siderations, when asked about the most appropriate anatomic
locations for monitoring BMD in the Delphi questionnaire,
consensus was reached on lumbar zone, femoral neck, and
total hip, while only femoral-neck area saw strong consensus
for both perspectives (wish and prognosis).
When fracture-risk reduction was used as the main param-
eter for defining an adequate therapeutic objective, there was
agreement that this parameter should be measured using
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FRAX. Like BMD, there was consensus that fracture risk
reduction should be measured either using a tangible percent-
age or as a predetermined difference between two values. As
far as the former is concerned, consensus was only achieved
on the value of risk of major fractures attained to be lower than
10%. It is noteworthy that consensus was not established for
the perspective of prognosis.
As regards BTM, there was consensus that they were good
therapeutic indicators for determining the therapeutic objec-
tive and performing treatment follow-up. However, from the
perspective of prognosis, consensus was established only on
their utility in treatment follow-up.
For both perspectives, there was consensus concerning
the utility of all parameters/techniques proposed for the
measurement of incidence of new fractures: vertebral frac-
ture analysis (VFA), height, conventional X-ray, major pe-
ripheral fragility fractures, or any fracture.
With regard to the optimal follow-up scheme, our re-
sults suggest that the best anatomic site for monitoring
densitometry was the femoral neck, although lumbar spine
obtained also a high participant wish score. In fact, this
reflects the expertise of participants in the Delphi study,
because it is well known that as precision and reproduc-
ibility are lower at lumbar spine, osteoarthritis and other
artifacts might affect results in older people, and there-
fore, in these cases, femoral neck could be a better choice
for measurement [32].
Experts reached consensus regarding the possibility of ap-
plying the T2T strategy in osteoporosis when the treatments
used are oral bisphosphonates, intravenous bisphosphonates,
and SERMs such as raloxifene or bazedoxifene, strontium
ranelate, denosumab, teriparatide, denosumab plus
teriparatide, or developing drugs. There was no consensus
with regard to the perspective of prognosis when strontium
ranelate was used. This result can perhaps be explained by the
fact that even though the studies with strontium ranelate show
a clear increase in BMD, its use has recently been restricted
and there is a chance that the drug will be removed from the
Spanish market.
The treatments for which the wish consensus scores were
highest were denosumab and teriparatide. This result could be
associated with its positive impact that has been reported in
recent studies published after long-term treatment with
denosumab alone [20, 33] or with combinations [34].
In reference to the treatment period, the experts agreed
that regardless of the treatment used, once the therapeutic
objective is accomplished, treatment should be stopped for
a period of time, and also disagreed that treatment should
be administrated indefinitely. It should be mentioned that
no consensus was achieved when SERM was used.
Meanwhile, in the case of teriparatide, there was also con-
sensus on changing the treatment when, following recom-
mendations to discontinue treatment, 18 or 24 months were
achieved. Additionally, this point reflects the experience of
participants, as these results are consistent with recent pub-
lications [35, 36]. BMD monitorization after target accom-
plishment by reversible drugs such as denosumab would
require further investigation. Denosumab is characterized
by reversal of effect, and is associated with a progressive
increase in vertebral fracture risk rate to levels comparable
with before the start of treatment. Consequently, in order to
prevent new factures, as has been reported by Anastasilakis
et al. [37], those who discontinue denosumab should
switch to another therapy after the 6 months dosing inter-
val [38, 39]. There was consensus regarding therapeutic
failure upon inability to achieve a clinically significant
increase of BMD for 2 or 3 years, when a new fracture
was diagnosed in the subsequent 1 to 5 years, or when a
significant change in BTM was not achieved in the follow-
ing 6 months or 1 year.
Strength and limitations
This study has several strengths and limitations. The main
limitation is related to the scope of the study, as it was per-
formed in Spain and the results may not be applicable to other
countries. It would be interesting to undertake a similar study
using the Delphi methodology with international experts and
to observe and compare the results.
The main strength of the study is related to the expertise of
the participants, as most of them were expert physicians with
long experience in osteoporosis and a large number of visits
per month. It is also important to note that high levels of
consensus were achieved in the first round, when participants
were unaware of other participants’ responses.
Although the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis (ESCEO) as-
serts that it is not currently feasible to apply a T2T strat-
egy in osteoporosis, they did nevertheless identify a need
to continue improving the treatment target for patients at
higher risk (Btarget-to-treat strategy^). They consider that
before approaching the real value of T2T strategy, it is
necessary, among other matters, to establish an interna-
tional consensus on intervention thresholds and a univer-
sally accepted definition regarding treatment failure.
Other experts recommended the formation of a task force,
composed of medical experts and representatives of phy-
sician and patient organizations, to explore the feasibility
of establishing osteoporosis treatment targets.
Conclusions
A wide and representative panel of experts established con-
sensus regarding therapeutic objectives, patient follow-up
Osteoporos Int (2018) 29:489–499 497
scheme, treatment-failure criteria, and appropriate treatment
choice to use in T2T strategy in Spain. Although there are
some aspects that require further analysis, this study provides
new original data, based on Delphi methodology, with which
to implement T2T strategy for the management of osteoporo-
sis in Spain.
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